Laboratorios Richmond S.A.C.I.F. Stock

Equities

RICH

ARLRIC300027

Pharmaceuticals

End-of-day quote Buenos Aires S.E. 06:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
874.5 ARS +0.17% Intraday chart for Laboratorios Richmond S.A.C.I.F. -9.10% +25.20%
Sales 2022 18.47B 21.2M Sales 2023 39.03B 44.8M Capitalization 56.4B 64.75M
Net income 2022 163M 187K Net income 2023 -10.85B -12.46M EV / Sales 2022 2.72 x
Net Debt 2022 18.9B 21.69M Net Debt 2023 93.33B 107M EV / Sales 2023 3.84 x
P/E ratio 2022
193 x
P/E ratio 2023
-5.2 x
Employees 620
Yield 2022 *
-
Yield 2023
-
Free-Float 17.54%
More Fundamentals * Assessed data
Dynamic Chart
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Laboratorios Richmond C I F : Argentina's Laboratorios Richmond supplies 1st batch of Russian vaccine RE
Russian Direct Investment Fund and Laboratorios Richmond Delivers the First Batch of over 1 Million Doses of the Sputnik V Vaccine Produced in Argentina to the Country's Ministry of Health CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Laboratorios Richmond C I F : Argentine lab strikes deal to produce Russia's Sputnik V vaccine RE
More news
1 day+0.17%
1 week-9.10%
Current month+2.94%
1 month+4.11%
3 months+4.86%
6 months+36.96%
Current year+25.20%
More quotes
1 week
841.50
Extreme 841.5
970.00
1 month
825.00
Extreme 825
990.00
Current year
664.00
Extreme 664
1 235.00
1 year
394.00
Extreme 394
1 235.00
3 years
208.50
Extreme 208.5
1 235.00
5 years
35.00
Extreme 35
1 235.00
10 years
24.80
Extreme 24.8
1 235.00
More quotes
Managers TitleAgeSince
Director/Board Member - -
Members of the board TitleAgeSince
Director/Board Member - -
Chairman - -
Director/Board Member - -
More insiders
Date Price Change Volume
24-04-19 874.5 +0.17% 7,057
24-04-18 873 -3.00% 20,723
24-04-17 900 +1.12% 1,438
24-04-16 890 -0.95% 5,302
24-04-15 898.5 -6.60% 2,938

End-of-day quote Buenos Aires S.E., April 18, 2024

More quotes
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
More about the company